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Introduction
Familial hypertrophic cardiomyopathy (HCM) is often referred to as a disease of the sarcomere, as a large num-
ber of mutations have been found in sarcomere-related genes (1). However, the mutations identified so far only 
account for ~50% of familial HCM cases (2), suggesting more candidate genes remain to be discovered. Fur-
thermore, although there are numerous transgenic mouse models of HCM, few of the published studies have 
followed the structural impact of HCM mutations on the sarcomeres prior to initiation of cardiac dysfunction in 
the adult. For instance, deleterious events unique to the embryonic heart may have lasting impact on the function 
of the adult myocardium. Moreover, identification of further genetic variants associated with HCM and greater 
understanding of disease progression will help in understanding the variability in HCM disease and penetrance.
Rho kinase (ROCK) is a serine/threonine protein kinase that is critical for regulating phosphorylation 
of  several sarcomeric proteins — myosin light chain 2 (Mlc2) (3), cardiac troponin I (cTnI), and cardiac 
Troponin T (cTnT) (4) — that all have important roles in regulating sarcomeric structure. There are 2 iso-
forms, ROCK1 and ROCK2, and they are the main downstream effectors of  the small Rho GTPase RhoA. 
The active form of  RhoA, GTP-RhoA, binds to the Rho-binding domain of  ROCK and hence can activate 
both of  these proteins. In addition to sarcomeric proteins, many proteins are phosphorylated by ROCK 
such that it is involved in a number of  diverse cellular activities, including actin cytoskeleton organization 
and muscle contraction (5), that are critical properties of  cardiomyocyte function. Therefore, as HCM 
mutations are believed to affect the efficiency of  sarcomere assembly (6) or cause sarcomere dysfunction 
including altered contractility (7), we hypothesized that the 2 ROCK isoforms would be ideal potential 
candidate genes for HCM if  their function were found to be disrupted in cardiomyocytes.
Both isoforms of  ROCK are expressed in the developing heart from the cardiac crescent stage at E7.5 
(8, 9) and are required for migration of  cardiac precursor cells (8). Although ROCK1- or ROCK2-null mice 
have been reported to be embryonic lethal, viability is influenced by genetic background (10–12). The role of  
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ROCK in cardiac hypertrophy and heart failure has previously been studied in adult mouse transgenic models 
with pathological-induced conditions, such as pressure overload–induced cardiac hypertrophy in the heart. 
Mouse models have implicated ROCK1 in the pathogenesis of  cardiac fibrosis (12) and the transition from 
cardiac hypertrophy to heart failure (13), and ROCK2 in regulating cardiac hypertrophy (14), in response to 
cardiac-targeted pathological-induced stimuli to induce cardiac hypertrophy. However, to our knowledge no 
studies to date have specifically focused on the endogenous role of  ROCK in embryonic cardiomyocytes in 
the absence of  any additional disease factors. Here we used the well-established ROCKDN mouse model (15) 
to target ROCK function in embryonic cardiomyocytes, using the same rationale as in our previous work (16, 
17), and tracked the long-term effect on cardiomyocyte function in the adult heart. Hence, we were able to 
study disease progression from initial onset during embryology to overt disease pathology associated with 
altered cardiac function. ROCKDN encodes a dominant negative ROCK protein that disrupts endogenous 
ROCK activity and is conditionally expressed in cells expressing Cre recombinase. We identified a mecha-
nism in ROCKDNGata5-Cre mutant mice, where there was disruption of  the sarcomeres in embryonic cardiomy-
ocytes, alongside reduced phosphorylation of  troponins and reduced cardiomyocyte proliferation. This led to 
delayed maturation and development of  the ventricular wall, and compensatory hypertrophy of  fetal cardio-
myocytes. The sarcomeric disruption and hypertrophy persisted into adulthood, subsequently transitioning to 
left ventricular (LV) dysfunction, emulating many of  the clinical and histological features of  HCM. Therefore, 
this transgenic mouse models the sarcomeric phenotype of  HCM where the transient developmental down-
regulation of  ROCK led to HCM in adult life, highlighting that HCM can have a developmental origin, which 
is clinically unidentifiable until the presentation of  the disease.
Results
Early downregulation of  ROCK function in cardiomyocytes led to defects in embryonic ventricular wall development. 
To evaluate ROCK expression in the embryonic heart, we used RNAscope probes specific for ROCK1 
and ROCK2, and showed that both isoforms were expressed uniformly in cardiomyocytes throughout the 
ventricular wall at E9.5 and E10.5 (Supplemental Figure 1, A–H; supplemental material available online 
with this article; https://doi.org/10.1172/jci.insight.125172DS1). Therefore, to investigate the function 
of  ROCK specifically within developing cardiomyocytes, we used the ROCKDN transgenic mouse model 
(15–21), bred with either TnT-Cre (22) or Gata5-Cre (23) transgenic mice and with WT1-ERT-Cre (24) trans-
genic mice to target ROCK function in the epicardium. Expression of  ROCKDN and removal of  the CAT 
box only in the presence of  Cre expression for each mouse cross were confirmed by quantitative real-time 
PCR (qRT-PCR) (Supplemental Figure 1, I–L).
In addition, the R262ReYFP reporter line (25) was used to track cells with Cre activity and confirmed uni-
form expression of TnT-Cre throughout cardiomyocytes at E10.5 (Supplemental Figure 2, A–D, and Supple-
mental Table 1A). 131 ROCKDNTnT-Cre mutant embryos were collected from E9.5 to E17.5 (Supplemental Table 
2A), and no mutant pups were collected from P0 onward. The is the first report to our knowledge to show that 
targeted disruption of ROCK activity in embryonic cardiomyocytes causes embryonic lethality. The phenotypes 
of the embryonic hearts were then examined by histology. In comparison to the control embryos, there were no 
obvious phenotypic differences in the development of the ventricular wall at E10.5 in ROCKDNTnT-Cre mutant 
embryos (Figure 1, E and M). However, from E11.5, the ventricular wall of the ROCKDNTnT-Cre mutant was visi-
bly thinner, with fewer trabeculae compared with the control embryo (Figure 1, F and M). Measurements of the 
thickness of the compact myocardium at E10.5–E15.5 showed that the compact myocardial wall from E12.5 in 
ROCKDNTnT-Cre embryos was significantly thinner, and remained significantly thinner at E14.5 and E15.5 (Figure 
1M). By E15.5, all the ROCKDNTnT-Cre hearts were dilated, with thin ventricular walls, no defined interventricular 
sulcus, and underdeveloped trabeculae (Figure 1, G and H). Externally, from E12.5, 12% of ROCKDNTnT-Cre 
embryos had edema, and by E15.5 this had increased to 23%, indicating inadequate cardiac function and pos-
sible heart failure (data not shown). This analysis showed that ROCK function is required in the embryonic 
cardiomyocytes for normal maturation and function of the ventricular wall from E11.5.
We speculated that the ROCKDNGata5-Cre mutants might have a milder viable phenotype compared with 
the ROCKDNTnT-Cre mutants, hence allowing investigation of  the impact of  embryonic ROCK downregula-
tion on the adult heart. This is because Gata5-Cre is expressed from E9.25 in a proportion of  the cardiomy-
ocytes. At E9.5, Cre expression was seen in 13% of  cardiomyocytes in the right ventricle and 19% in the 
left ventricle (Supplemental Figure 2, E–H), rising to 55% and 68%, respectively, by E15.5 (Supplemental 
Table 1B). Furthermore, we would have the benefit of  mosaicism, which allows cardiomyocytes in which 
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ROCK function is disrupted to be directly compared with genetically unaffected cardiomyocytes within the 
same heart. However, Gata5-Cre is also expressed in the epicardium from E9.25 (23). As we wanted to dis-
criminate the cardiomyocyte-specific function from any indirect epicardial role, we first confirmed that loss 
of  ROCK activity in the epicardium did not affect the myocardium. Cre expression was activated at E9.5 
in ROCKDNWT1-ERT-Cre litters, and the embryos were collected at E15.5. Cre expression was confirmed in the 
epicardium and epicardial derived cells (Supplemental Figure 2, M and N). However, no heart defects and 
in particular no ventricular wall defects were identified in any of  the ROCKDNWT1-ERT-Cre mutant embryos 
(Supplemental Figure 2, O and P). Thus, ROCK function in the epicardium was not essential for ventric-
ular wall maturation at this stage of  development, and any heart defects identified in the ROCKDNGata5-Cre 
mutants were due to the Cre expression in the cardiomyocytes of  the ventricular wall.
ROCKDNGata5-Cre mutants and control littermates were collected from E9.5 to adulthood: 380 mutant 
embryos, 67 mutant postnatal pups up to 1 month, and 38 mutant adults aged 2–16 months. At each age, 
the proportions of  ROCKDNGata5-Cre mutants were all within the expected Mendelian ratios, and there were 
no sudden deaths (Supplemental Table 2B), showing that ROCKDNGata5-Cre mutants survived embryogenesis 
and developed into adult mice.
Figure 1. Downregulation of ROCK1 and ROCK2 in embryonic cardiomyocytes leads to defects in the ventricular wall during embryogenesis. (A–L) 
Transverse sections from embryos were stained with H&E, and a representative high-power image of the right ventricle is shown for each genotype 
and embryonic age. At E10.5, the heart morphology was comparable among controls (A) and ROCKDNTnT-Cre (E) and ROCKDNGata5-Cre (I) mutants. A reduc-
tion in myocardial thickness was visually evident throughout both ventricles at E11.5 in ROCKDNTnT-Cre (arrow in F) and ROCKDNGata5-Cre (arrow in J) mutant 
hearts compared with control hearts (B). Reduced myocardial thickness was still present at E15.5 in ROCKDNTnT-Cre (G and H) and ROCKDNGata5-Cre (K and 
L) mutants compared with control hearts (C and D). The ROCKDNTnT-Cre mutants had no defined interventricular sulcus (arrow in G). The severity of 
myocardial wall thickness was more prominent in ROCKDNTnT-Cre hearts than ROCKDNGata5-Cre mutants (compare arrows in H and L). (M and N) Myocardial 
wall measurements confirmed that the compact myocardium was significantly thinner in ROCKDNTnT-Cre mutants at E12.5, E14.5, and E15.5 (M), and at 
E14.5 and E15.5 in ROCKDNGata5-Cre mutants (N), compared with littermate control embryos. E10.5 n = 5, E11.5 n = 5, E12.5 n = 5, E14.5 n = 5, E15.5 n = 5 for 
ROCKDNTnT-Cre mutants and littermate controls; and E10.5 n = 6, E11.5 n = 6, E12.5 n = 6, E14.5 n = 5, E15.5 n = 12 for ROCKDNGata5-Cre mutants and litter-
mate controls. Data are presented as mean ± SEM. **P < 0.01, ****P < 0.0001 by 1-way ANOVA with Bonferroni’s correction for multiple comparisons. 
rv, right ventricle; lv, left ventricle. Scale bars: 100 μm.
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Expression analysis of  hearts from ROCKDNGata5-Cre mutants and control littermates showed that ROCKDN 
was strongly expressed in the mutants until P21, with a significant drop in expression levels between each time 
point until 3 months (Supplemental Figure 3A). Therefore, any defects seen in the adult hearts were not due to 
disruption of  ROCK signaling in adulthood. No change in Cre expression or endogenous ROCK1 and ROCK2 
expression was seen between control and mutant hearts in embryos or adults (Supplemental Figure 3, B–D).
Examination of  the embryos by histology revealed that at E10.5, hearts from ROCKDNGata5-Cre mutants 
were comparable to those from control littermates (Figure 1, A and I). However, there was visible thinning 
of  the ventricular wall throughout the heart beginning at E11.5, which was very similar to the ROCKDNTnT-Cre 
mutants at the same age (Figure 1, F and G), and also evident at E14.5 and E15.5 (Figure 1, K, L, and N). 
Further detailed analysis of  the LV and right ventricular (RV) walls, individually, showed that in control 
embryos from E15.5 the compact myocardial wall thickened steadily up to P21, with no significant difference 
in cell size between E15.5 and E16.5 (blue lines, Figure 2, A and B). In comparison, the thickness of  the 
compact myocardium of the ROCKDNGata5-Cre mutants increased significantly between E15.5 and E16.5 in both 
Figure 2. Impaired maturation of the ventricular wall in late fetal and postnatal ROCKDNGata5-Cre mutants. (A and B) Measurements of the compact myocar-
dial wall were performed on transverse heart sections from E15.5 (n = 12), E16.5 (n = 5), and E17.5 (n = 4) embryos, and P0 (n = 3), P4 (n = 3), P7 (n = 3), and P21 
(n = 4) postnatal pups, in both the left ventricle (A) and right ventricle (B), in control and ROCKDNGata5-Cre mutant littermates. During embryonic and postnatal 
development, generally, the compact myocardium of the control hearts is thicker than in mutant hearts. In particular, in the left ventricle, the control compact 
myocardium is significantly thicker than in the ROCKDNGata5-Cre mutant compact myocardium at E15.5, P4, P7, and P21 (A); and in the right ventricle it is signif-
icantly thicker at E15.5, P7 and P21 (B). From E15.5 to E16.5 in ROCKDNGata5-Cre mutant hearts, myocardial wall thickness increased significantly, in both the left 
ventricle and right ventricle (red lines), whereas no corresponding significant increase was observed in control hearts (blue lines). (C–F) High-resolution epis-
copic microscopy imaging at E15.5 showed that ROCKDNGata5-Cre hearts (D and F) displayed an immature thin myocardial wall containing myocardial crypts with-
in the compact myocardium (red arrows F) compared with controls (C and E). n = 10 for each genotype. (G–J) Phenotypic analysis of 4-chamber view sections 
from postnatal hearts, stained with the histological stain H&E, confirmed that in the ROCKDNGata5-Cre hearts the ventricular wall was visibly thinner and that 
it also contained myocardial crypts (arrows) at P0 and P21. n = 3 for each genotype at each time point. (K) Trabecular complexity for each heart was assessed 
by calculating the ratio of trabecular myocardial area to compact myocardium area throughout the ventricles. There were no significant differences between 
control and mutant hearts during fetal and postnatal development, confirming that ROCKDNGata5-Cre mutants did not have a non-compaction phenotype. E15.5 
(n = 8), E17.5 (n = 6), P0, and P21 (n = 3) for each genotype at each time point. Data are presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 
0.0001 by 1-way ANOVA with Bonferroni’s correction for multiple comparisons. lv/LV, left ventricle; rv/RV, right ventricle. Scale bars: 100 μm.
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ventricles (red lines, Figure 2, A and B). However, in comparison to control hearts, from E16.5, there was a 
trend for the LV and RV walls in the ROCKDNGata5-Cre mutants to remain thinner, and they were significantly 
thinner in both ventricles at P7 and P21. At E15.5, the ROCKDNGata5-Cre mutant hearts had persisting immature 
trabeculae that were more pronounced than those in the control hearts, forming myocardial crypts, which are 
discrete clefts in the compact myocardium (Figure 2, C–F). These myocardial crypts remained more prevalent 
in the ROCKDNGata5-Cre mutants in postnatal hearts (Figure 2, G–J), as no crypts were seen in control hearts. All 
of  these structural phenotypic differences in the ventricular wall were identified in all of  the ROCKDNGata5-Cre 
mutants examined at each age. To confirm that the ROCKDNGata5-Cre mutants did not have a noncompaction 
phenotype (highly trabeculated myocardium with prominent deep intertrabecular recesses), we used an estab-
lished method to measure trabecular complexity (26). No significant increase in trabecular complexity was 
observed in ROCKDNGata5-Cre fetal or postnatal mutant hearts compared with control hearts (Figure 2K). Thus, 
the results confirmed that these mice had a delay in maturation of  the ventricular wall in ROCKDNGata5-Cre 
mutants, as the compact myocardium failed to thicken and some trabeculae did not compact fully.
Disruption of  ROCK signaling leads to a delay in maturation of  the ventricular wall. As chemical inhibition of  
ROCK during mouse embryo culture had previously shown a decrease in proliferation in the whole heart 
(9), we speculated that the cause of  the thin myocardium in the ROCKDNGata5-Cre mutants was due to reduced 
cardiomyocyte proliferation and/or increased apoptosis. Therefore, we examined these processes in embry-
onic hearts at E10.5 and E11.5, coinciding with the first visual appearance of  an abnormal ventricular 
wall in the ROCKDNGata5-Cre mutants at E11.5. No significant difference in proliferation was seen at E10.5; 
however, there was a significant decrease in proliferation specifically in Cre-activated cardiomyocytes in the 
compact myocardium of  both ventricles at E11.5 in the ROCKDNGata5-Cre mutants (Figure 3, A–C). There 
was no change in Cre-negative proliferating cardiomyocytes and no difference in cell death using caspase-3 
antibody staining (data not shown). Thus, the decrease in proliferation at E11.5 accounted for the subse-
quent thinning of  the compact myocardium.
To explain the significant increase in compact wall thickness between E15.5 and E16.5 in ROCKDN-
Gata5-Cre mutants (Figure 2, A and B), we first hypothesized that there may be a “catch-up” acceleration in 
proliferation between these two ages. However, no significant differences in the percentage of  all prolifer-
ating cardiomyocytes in the compact myocardium of  the LV or RV was detected at either age (Figure 3D). 
Furthermore, cell counts from the compact myocardium showed that the average number of  cardiomyo-
cytes per field of  view was significantly smaller throughout the heart at E16.5 and E17.5 in ROCKDNGata5-Cre 
mutants (Figure 3E). The increase in thickness between E15.5 and E16.5 in ROCKDNGata5-Cre mutants might 
therefore be due to an increase in cardiomyocyte hypertrophy.
At E16.5, cardiomyocytes were, on average, significantly larger (16% and 12%) in the LV and RV, 
respectively, in ROCKDNGata5-Cre mutants compared with control cardiomyocytes (Figure 3, F, G, K, and 
L, and Supplemental Table 3A). This increase in hypertrophy was seen in both Cre-activated (green) and 
Cre-negative cardiomyocytes (unstained) (Figure 3, H–J), suggesting that all the cardiomyocytes were 
undergoing compensatory hypertrophy in order to maintain adequate cardiac function. In subsequent post-
natal stages (up to P21), all of  the cardiomyocytes remained significantly hypertrophic in the ROCKDNGa-
ta5-Cre mutants compared with the controls (Figure 3, K and L).
Markers of  cardiomyocyte maturity were examined to establish whether this process was delayed in 
the ROCKDNGata5-Cre mutants. In agreement with published data (27), in control hearts, α–smooth muscle 
actin (α-SMA) was restricted to the compact myocardium by E15.5 and to smooth muscle of  the coronary 
arteries by P4 (Figure 4, A–E). In ROCKDNGata5-Cre mutants, however, α-SMA was still expressed in trabec-
ulae at E15.5 and E17.5 (Figure 4, F, G, and K), and patchy staining throughout the ventricular wall was 
still evident at P7 (Figure 4J). Thus, disruption of  ROCK function leads to a delay in the maturation of  the 
cardiomyocytes. Therefore, embryonic cardiomyocytes require ROCK function for normal development 
and maturation of  trabeculae and compact myocardium from E11.5.
Reduced ROCK signaling causes disruption of  sarcomeres in cardiomyocytes from E10.5 in ROCKDNGata5-Cre and 
ROCKDNTnT-Cre mutants. Having established that in both ROCKDNGata5-Cre and ROCKDNTnT-Cre mutants a defect in 
the structure of the ventricular wall is first visible from E11.5, we then looked a day earlier at E10.5 to establish 
what intracellular abnormalities may have led to the abnormal wall development. We first looked at the integrity 
of sarcomeres in the ROCKDNGata5-Cre mutants. At E9.25, when Gata5-Cre was first expressed, the expression 
pattern of cTnI was identical in control and ROCKDNGata5-Cre mutants in all cardiomyocytes, irrespective of Cre 
activation (Supplemental Figure 4, A–D). In control hearts at E10.5, sarcomeres, identified by cTnI antibody 
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Figure 3. Reduced proliferation of cardiomyocytes followed by increased cardiomyocyte hypertrophy leads to abnormal ventricular wall development 
in ROCKDNGata5-Cre mutants. (A and B) Transverse sections from control and ROCKDNGata5-Cre mutant embryos collected from mothers injected with BrdU 
were stained with BrdU antibody to label proliferating cells (green staining) and GFP antibody to stain Cre-activated cells (red staining). The total number 
of Cre-activated cardiomyocytes and total number of proliferating Cre-activated cardiomyocytes, in which ROCK was downregulated, were determined in 
each sample, from which the percentage of proliferating Cre-activated cardiomyocytes was calculated. A representative image of the left ventricle from 
E11.5 embryos is shown. (C) No significant difference in the percentage of proliferating Cre-activated cardiomyocytes was detected in the left or right ven-
tricle at E10.5. At E11.5 there was a significant decrease in the percentage of proliferating Cre-activated cardiomyocytes in ROCKDNGata5-Cre mutants, in both 
the left and right ventricles compared with controls. n = 6 for each genotype at both time points. (D) No significant difference in cardiomyocyte prolifera-
tion was identified in ROCKDNGata5-Cre hearts at either E15.5 or E16.5. n = 3 for each genotype at both time points. (E) The average number of cardiomyocytes 
in the compact myocardium, per field of view, was calculated at E15.5, E16.5, and E17.5 and showed a significant decrease in the number of cardiomyocytes 
in ROCKDNGata5-Cre hearts at E16.5 and E17.5 in both the left and right ventricle, compared with controls. n = 3 for each genotype at all time points. (F and G) 
Wheat germ agglutinin (WGA) immunofluorescence was used to determine cardiomyocyte cell size in control and ROCKDNGata5-Cre hearts. The cardiomy-
ocytes in ROCKDNGata5-Cre hearts (G) were visibly larger than those in control hearts (F). In ROCKDNGata5-Cre hearts, both Cre-activated/GFP+ (GFP+ve) (green 
staining) (example cell outlined in yellow in H–J) and GFP– (GFP-ve; example cell outlined in white cell in H–J) cardiomyocytes were hypertrophic. (K and L) 
In ROCKDNGata5-Cre hearts, the cardiomyocytes in the compact myocardium were significantly larger compared with control hearts, from E16.5 to P21 in the 
left ventricle (K) and from E15.5 to P7 in the right ventricle (L). n=5 for E15.5 and E16.5; n = 4 for E17.5 and P21; n = 3 for P0, P4, and P7 for each genotype. 
Data are presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 by 1-way ANOVA with Bonferroni’s correction for multiple compari-
sons. lv/LV, left ventricle; RV, right ventricle. Scale bars: 100 μm (A and B), 50 μm (F and G), and 20 μm (H–J).
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staining, appeared to be close to the cell membrane, as previously reported (28), in all cardiomyocytes (Figure 
5, B and H). Fluorescence intensity analysis using ImageJ confirmed that in control embryos, cTnI staining 
was restricted close to the cardiomyocyte cell membrane, as shown by the two separate peaks at either side of  
the fluorescence intensity plot (Figure 5E). In contrast, in Cre-activated (GFP+) cardiomyocytes in ROCKDN-
Gata5-Cre mutants, the staining patterns of the sarcomeres were no longer restricted to the edges of the cells (Fig-
ure 5D); cTnI expression now appeared throughout the cell (Figure 5F). In contrast, staining patterns in Cre– 
(GFP–) cardiomyocytes in the ROCKDNGata5-Cre mutants were identical to the cardiomyocytes in control embryos, 
thus confirming that mislocalization of sarcomeric proteins at E10.5 was restricted to the cardiomyocytes in 
which ROCK function had been disrupted (Figure 5, G–J). To verify these data, we repeated the analysis using 
ROCKDNTnT-Cre mutants at E9.5 and E10.5, in which Cre was active throughout all of the cardiomyocytes. Stain-
ing at E9.5 showed comparable cTnI expression in the ventricular walls of control and ROCKDNTnT-Cre mutant 
embryos (Supplemental Figure 4, E–H). However, similar to the ROCKDNGata5-Cre Cre-activated cardiomyocytes, 
in ROCKDNTnT-Cre mutants at E10.5, cTnI expression was mislocalized in all cardiomyocytes throughout the ven-
tricular wall (Supplemental Figure 4, I–L). Therefore, we showed that loss of ROCK function by both mosaic 
cardiomyocyte expression of Gata5-Cre and uniform cardiomyocyte expression of TnT-Cre affected the intracel-
lular structure of sarcomeres in embryonic cardiomyocytes at E10.5.
In order to confirm that the mislocalization of  sarcomeres, first seen at E10.5, represented sarcomere 
disarray in ROCKDNGata5-Cre cardiomyocytes, we examined sarcomeres at E10.5 by transmission electron 
microscopy (TEM). In control cardiomyocytes of  the compact myocardium, the myofibrils were clearly 
defined, with long, continuous arrays of  sarcomeric repeating units, separated by Z lines, and were gen-
erally found close to the cell membrane (Figure 5K). In comparison, sarcomeres in the ROCKDNGata5-Cre 
mutants were dispersed throughout the cell and were disorganized (Figure 5L). The sarcomeric structures 
were quantified (29), and in ROCKDNGata5-Cre mutants they were significantly longer and thinner than in 
control sarcomeres (Figure 5S), with significantly fewer repeating sarcomeric units per sarcomere (Figure 
5T); the sarcomeres were separated by less-well-defined, diffuse Z lines (arrows in Figure 5N), which were 
significantly wider compared with control hearts (Figure 5U). In addition, there was structural myofibril 
discontinuity at the intercalated discs, which serve as the site of  myofibril connection between neighbor-
ing cardiomyocytes, in the ROCKDNGata5-Cre mutants. These myofibrils approached the intercalated disc at 
different angles, causing a disorganized or detached morphology (Figure 5, P and V). Within a single 
cardiomyocyte in the ROCKDNGata5-Cre mutants, there was a mixture of  normal and abnormal sarcomeres 
(Supplemental Figure 4, M and N). The destabilized structure of  sarcomeres in the ROCKDNGata5-Cre mutants 
suggests that the process of  myofibrillogenesis may have been impaired, and was also associated with a 
reduction in myofibril density (Figure 5W) (30) and a significant increase in areas of  G-actin accumulation 
(29) (which normally forms the F-actin of  the thin filament; Figure 5, R and X). At E15.5, myofibrils in the 
ROCKDNGata5-Cre mutants were again thinner and disjointed compared with the uniformly arranged sarco-
meres in the control (Supplemental Figure 4, O and P). Likewise, in ROCKDNTnT-Cre mutants, TEM showed 
that the sarcomeres were abnormal at E10.5 (Supplemental Figure 4, Q and R). Taken together with the 
immunofluorescence data, this confirmed that downregulation of  ROCK in cardiomyocytes caused disrup-
tion of  sarcomere integrity in the ventricular wall as early as E10.5.
In order to establish whether disruption of  sarcomeres by loss of  ROCK signaling can trigger cardio-
myocyte hypertrophy in a cell-autonomous manner, we used an in vitro approach. We cultured primary 
embryonic cardiomyocytes from control E17.5 embryos in serum-supplemented media and treated them 
with the ROCK inhibitor Y27632 (31). There was loss of  sarcomeres, and the cardiomyocytes were signifi-
cantly larger in ROCK inhibitor–treated cardiomyocytes compared with untreated control cardiomyocytes 
(Figure 6, A–C). Furthermore, the composition of  the actin cytoskeleton was altered in the ROCK inhib-
itor–treated cardiomyocytes. There was a significant reduction in F-actin (stained by phalloidin; Figure 6, 
H and M) and an increase and altered cellular localization of  G-actin (stained by DNase I; Figure 6, I–L). 
Therefore, this supports the idea that in vivo, reduced ROCK signaling altered the intracellular actin of  the 
thin filaments and led to the early disruption of  sarcomere structures, which may have subsequently led to 
the compensatory cardiomyocyte hypertrophy we observed at E16.5 onward in ROCKDNGata5-Cre mutants.
Disruption of  sarcomere structure may be due to altered phosphorylation of  the troponin complex. As ROCK is known 
to phosphorylate the sarcomeric proteins cTnI, cTnT, and Mlc2 (3, 4) and because disruption of ROCK sig-
naling in embryonic cardiomyocytes led to abnormal sarcomeric structure, we reasoned this may be linked to 
altered phosphorylation of these sarcomeric proteins. Therefore, we assessed whether phosphorylation of cTnI, 
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cTnT, and Mlc2 was altered in the hearts of E13.5 ROCKDNGata5-Cre mutants, using Pro-Q Diamond (Invitrogen) 
phosphoprotein stain, by determining the relative amount of phosphorylated protein to overall total protein 
concentration (Figure 7, A and B). As there are multiple bands on the Pro-Q gel, the same gel was transferred 
and blotted with the corresponding unphosphorylated antibodies to identify the correct band for analysis for 
each protein of interest (Figure 7C). ROCKDNGata5-Cre hearts showed a significant decrease in the level of phos-
phorylated cTnI (ph-cTnI) and phosphorylated slow skeletal TnI (ph-ssTnI) expression (Figure 7, D and E) 
but no significant difference in ph-cTnT (Figure 7F). ROCKDNTnT-Cre mutants displayed a significant decrease in 
ph-cTnI, ph-ssTnI, and ph-cTnT (Figure 7, H–J). No change in phosphorylation of Mlc2 was observed in either 
ROCKDN mutant mouse line (Figure 7, G and K). These results were confirmed in vitro using protein extracted 
from primary mouse cardiomyocytes treated with the ROCK inhibitor Y27632. There was significantly reduced 
phosphorylation of cTnI, ssTnI, and cTnT, but not Mlc2 (Figure 7, L–O). Immunofluorescence using a phos-
pho-specific TnI antibody confirmed reduced levels of ph-cTnI in Cre-activated cardiomyocytes at E10.5, prior 
to onset of a phenotype, in ROCKDNGata5-Cre hearts (Figure 8, A–F). Thus, in the presence of ROCKDN protein, 
there was reduced phosphorylation of both isoforms of TnI and cTnT in embryonic cardiomyocytes.
Figure 4. Delayed maturation of cardiomyocytes in ROCKDNGata5-Cre mutants. (A–E) The pattern of α-SMA expression was investigated by immunohisto-
chemistry and visualized by DAB staining, and a representative image of the left ventricular wall, from each age, is shown. In control hearts at E15.5 and 
E17.5, α-SMA became restricted to the compact myocardium and was no longer expressed in trabeculae (arrows in A and B). Postnatally, expression was 
further restricted to the smooth muscle of coronary arteries, with no cardiomyocyte staining by P7 (C–E). In contrast, in ROCKDNGata5-Cre mutants, α-SMA 
staining persisted in trabeculae at E15.5 and E17.5 (arrows in F and G), and there were patches of cardiomyocyte expression postnatally (arrows in H–J). (K) 
The level of α-SMA expression was measured by ImageJ in trabeculae and in the compact myocardium. The total area of trabeculae or the compact myo-
cardium was measured throughout the heart, and the percentage of this area in which α-SMA was expressed was calculated. This confirmed that α-SMA 
expression was retained longer in trabeculae in ROCKDNGata5-Cre mutants, as there were significantly higher levels of α-SMA expression at E15.5 and E17.5 
in trabeculae of mutants compared with trabeculae of littermate controls. Furthermore, in control hearts at E15.5, there was a significant difference in 
α-SMA expression levels between trabeculae and the compact myocardium (blue line), confirming, as expected, that the expression was becoming restrict-
ed to the compact myocardium. In contrast, in ROCKDNGata5-Cre mutants, there was no significant difference between expression levels in trabeculae and 
compact myocardium (purple line; NS). By E17.5, there was a significant difference in expression levels in the compact myocardium between controls and 
mutants, showing that, as expected, expression in control hearts was beginning to decrease in the compact myocardium as the cardiomyocytes matured 
and that this process was delayed in ROCKDNGata5-Cre mutants. n = 8 for E15.5 and n = 6 for E17.5 for each genotype. Data are presented as mean ± SEM. *P < 
0.05, **P < 0.01, ****P < 0.0001 by 1-way ANOVA with Bonferroni’s correction for multiple comparisons. lv, left ventricle. Scale bars: 100 μm.
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Figure 5. Destabilization of sarcomeres in ROCKDNGata5-Cre mutant cardiomyocytes at E10.5. (A–J) Transverse sections from E10.5 embryos were stained 
by immunofluorescence to identify all cardiomyocytes (cTnI staining, green) and Cre-activated cardiomyocytes/GFP+ cells (red staining). In Cre-activated 
cardiomyocytes of control embryos, cTnI was cortical (red arrows in B), confirmed by the 2 separate curves in the fluorescence intensity profile plot (E). In 
contrast, in Cre-activated cardiomyocytes of ROCKDNGata5-Cre mutants, cTnI staining was disrupted, as it was diffuse throughout the cell (red arrows in D), 
confirmed by the continuous line in the fluorescence intensity profile plot (F). The cTnI staining in GFP negative cardiomyocytes in control and ROCKDNGa-
ta5-Cre mutants was identical (white arrows in G–J). n=6 for each genotype. (K–R) Representative TEM imaging of myofibrils at E10.5. In controls, the sarco-
meres generally align in close proximity to the plasma membrane and are highly organized (arrows in K). In ROCKDNGata5-Cre cardiomyocytes, the myofibrils 
are located throughout the cells and show sarcomere collapse (arrows in L). The average width of the Z discs throughout the sarcomeres was significantly 
increased in ROCKDNGata5-Cre cardiomyocytes compared with controls (M, N, and U). Myofibril discontinuity was present at cellular junctions in ROCKDNGa-
ta5-Cre as the myofibrils approached the intercalated discs at more varied wider angles (arrows in P and V) but not seen in controls (O). Areas of G-actin accu-
mulation were detected in ROCKDNGata5-Cre cardiomyocytes (R) more frequently that in control hearts (Q) giving a significant increase in G-actin density (X). 
(S) There was a significant increase in sarcomere length and decrease in sarcomere width in ROCKDNGata5-Cre mutants compared with sarcomeres in control 
hearts. (T) The number of repeating sarcomeric units, per field of view in comparative regions, was significantly reduced in ROCKDNGata5-Cre cardiomyocytes. 
(W) As a consequence of the abnormal sarcomeric structure, in ROCKDNGata5-Cre cardiomyocytes, there was significantly reduced myofibril density per field 
of view. (X) The percent area containing G-actin, per field of view, showed a significant increase in ROCKDNGata5-Cre cardiomyocytes. n = 5 for each genotype. 
lv, left ventricle; pm, plasma membrane. Data are presented as mean ± SEM. **P < 0.01, ***P < 0.001, ****P < 0.0001 by unpaired t test. Scale bars: 50 
μm (A–D and G–J) and 500 nm (K–R).
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co-IP confirmed that in embryonic hearts, ROCK1 and ROCK2 proteins bind to TnT, cTnI, and ssTnI 
(Figure 8, G and H), and that the interaction between ROCK1 and the 2 isoforms of  TnI was significantly 
reduced in ROCKDNGata5-Cre hearts (Figure 8, H–L). Thus, this may account for the reduced levels of  phos-
phorylation observed in ROCKDNCre hearts.
It is not clear whether phosphorylation of  the troponin proteins is key to the formation of  sarco-
meres. To start to address this question, we treated control and ROCKDNGata5-Cre primary cardiomyo-
cytes with the drug IBMX, which is known to increase phosphorylation of  TnI through the activation 
of  protein kinase A (32). In control and ROCKDNGata5-Cre Cre– cardiomyocytes, IBMX did not signifi-
cantly alter the average number of  sarcomeres per cardiomyocyte (Figure 8, K, N, W, and Y). Howev-
er, addition of  IBMX significantly rescued the number of  sarcomeres in ROCKDNGata5-Cre Cre-activated 
cardiomyocytes from zero (Figure 8Q) to an average number of  sarcomeres similar to that in control 
cardiomyocytes (Figure 8, T and Y). This suggests that the phosphorylation of  the troponins may 
impact on sarcomere formation in embryonic cardiomyocytes.
Figure 6. Loss of sarcomere structure and increased hypertrophy in primary cardiomyocytes after treatment with the ROCK inhibitor Y27632. Primary 
cardiomyocytes from E17.5 control embryos were cultured, and half were treated with the ROCK inhibitor Y27632. Cardiomyocytes were identified by stain-
ing with cTnI antibody, which stains sarcomeres (green). In the control group, the organized structure of the sarcomeres was clearly visible (A), whereas 
addition of Y27632 abolished the sarcomeric structure, and the cardiomyocytes appeared hypertrophic (B) compared with untreated control cardiomyo-
cytes. (C) Cardiomyocyte area was calculated using ImageJ. The average cell area was calculated from a total of 10 cells from each treatment group, and 
the measurements confirmed that there is a significant increase in cell size with the addition of Y27632. n=4. (D–I) To analyze the actin composition of the 
cultured cardiomyocytes, we stained for G-actin (DNase I, green staining) and F-actin (phalloidin, red staining). Staining of both phalloidin (H) and DNase I 
(I) was disrupted in Y27632-treated cardiomyocytes, with loss of F-actin in the cytoplasm and an accumulation of DNase I around the nuclear membrane, 
illustrated by the fluorescence intensity profile plots (J and K). Fluorescence intensity measurements confirmed there was a significant increase in DNase 
I staining (L) and a decrease in phalloidin staining (M). n = 3 biological replicates for primary cardiomyocytes. Data are represented as mean ± SEM. *P < 
0.05, **P < 0.01, ***P < 0.001 by unpaired t test. Scale bars: 20 μm (A, B, and D–I).
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ROCKDNGata5-Cre mutant mice develop LV hypertrophy and dysfunction in adulthood. Despite the presence 
of  sarcomeric disruption and embryonic ventricular wall abnormalities, the ROCKDNGata5-Cre mutant mice 
all survived to adulthood. Having established that cardiomyocytes in the ROCKDNGata5-Cre mutant hearts 
were significantly hypertrophic compared with control hearts in late fetal development and postnatally 
(Figure 3), we extended this analysis to older mice to determine whether the hypertrophy persisted and 
if  it increased further with age. At 4–12 months, cardiomyocytes in the ROCKDNGata5-Cre mutant hearts 
continued to be significantly larger than those in control hearts at each time point (Figure 9, A and B, 
and Supplemental Table 3A). Interestingly, up to 4 months, the percent increase in cell size compared 
Figure 7. Downregulation of ROCK function leads to decreased phosphorylation of TnI and cTnT in vivo and in vitro. Pro-Q Diamond phosphoprotein 
stain was used to determine the total amount of the phosphorylated form of each protein (A), and Coomassie blue was used to determine total amount 
of each protein (B) at E13.5 in control, ROCKDNGata5-Cre, and ROCKDNTnT-Cre mutant hearts and in isolated primary mouse cardiomyocytes treated with and 
without the ROCK inhibitor Y27632. Representative gel images are shown for each type of sample analyzed. (C) Western blot analysis of the same blot 
shown in A and B, using specific antibodies, confirmed that the correct bands on the Pro-Q and Coomassie blue blots (arrows in A and B) were measured by 
densitometry for the proteins of interest: cTnT 40 kDa, cTnI 26 kDa, ssTnI 22 kDa, and Mlc2 18 kDa. (D–O) The relative amount of phosphorylated protein to 
total protein was calculated using densitometry for control and mutant heart or cell samples. A significant reduction in ph-cTnI and ph-ssTnI was observed 
in ROCKDNGata5-Cre (D and E) compared with controls. A significant reduction in ph-cTnI, ph-ssTnI, and additionally ph-TnT was observed in ROCKDNTnT-Cre 
mutants (H–J) compared with controls. Primary cardiomyocytes from E17.5 control embryos treated with Y27632 also showed a significant reduction in 
ph-cTnI (L), ph-ssTnI (M), and ph-TnT (N). No change in the levels of ph-Mlc2 was observed in any of the groups (G, K, and O). n = 4 for each genotype and n 
= 3 biological replicates for primary cardiomyocytes. Data are presented as mean ± SEM. *P < 0.05, **P < 0.01 by unpaired t test. CM, cardiomyocytes.
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with control cardiomyocytes was similar in each of  the 2 ventricles, but this became asymmetrical from 
9 months. The increase in cardiomyocyte size in the LV increased significantly from 27% at 4 months 
to 43% at 9 months compared with only a nonsignificant increase from 22% to 30% in the RV. At 12 
months, there was a further increase to 52% in the LV, while the RV remained at 31% (Figure 9, C and 
D, and Supplemental Table 3B). No corresponding increase in hypertrophy was seen in control hearts. 
Thus, there was a specific asymmetric increase in LV hypertrophy from 9 months.
Re-expression of  fetal genes is associated with hypertrophy in cardiomyopathy (33), and therefore, we 
looked at gene expression levels in adult ROCKDNGata5-Cre hearts from 1 to 12 months. A panel of  genes were 
chosen that included fetal genes known to be re-expressed in ventricular hypertrophy (ANF and Myh7) and 
genes known to be dysregulated during hypertrophy (skeletal actin and phospholamban). In ROCKDNGata5-Cre 
mutants, there was a significant increase in expression of  ANF and Myh7 and a significant decrease in expres-
sion of  skeletal actin and phospholamban (Figure 9, E–H). These changes are all associated with hypertro-
phy and cardiac pathogenesis and coincide with the significant rise in hypertrophy observed at 9 months.
Antibody staining showed that sarcomeres were disrupted at E10.5 in ROCKDNGata5-Cre mutant embry-
onic hearts, and therefore, we focused on the older hearts to establish whether this intracellular abnormality 
was retained. Clear sarcomeric staining was observed in control hearts (Figure 9I and Supplemental Figure 
5, A–C), whereas there was loss of  this staining throughout the heart in the ROCKDNGata5-Cre mutants from 
P21 to 12 months (Figure 9J and Supplemental Figure 5, D–F). TEM analysis of  16-month hearts con-
firmed that there was disruption of  the uniform pattern of  repeating sarcomeres in ROCKDNGata5-Cre mutant 
hearts (Supplemental Figure 5, G–J), and mutant sarcomeres were now significantly shorter and wider than 
in controls (Supplemental Figure 5, K and L).
Histological analysis of  the adult hearts revealed there was no significant increase in fibrosis present 
until 9 months, at which point patches of  interstitial fibrotic staining were seen in both the LV and RV, only 
in ROCKDNGata5-Cre mutants, compared with control hearts (Figure 9, K–M, and Supplemental Figure 5, 
M–R). At each age there was positive staining in the valve tissue (data not shown). There was no accumu-
lation of  fat deposits in adult hearts (from 4 to 12 months) of  ROCKDNGata5-Cre mutants or controls (Supple-
mental Figure 5, S–V, and data not shown).
Despite the continued presence of  intracellular abnormalities, increasing cellular hypertrophy, and 
fibrosis with age, ROCKDNGata5-Cre mice appeared phenotypically healthy and indistinguishable from lit-
termate controls at all ages. In order to assess whether these early cardiac developmental defects had any 
underlying impact on the adult heart, functional analysis was carried out by MRI. Reduced cardiac func-
tion was seen from 10 months in ROCKDNGata5-Cre mutants, with a significant decrease in left (31.2 μl) and 
right (32.4 μl) stroke volumes (Figure 10, A and B); this resulted in significantly reduced cardiac output 
(Figure 10C), which also contributed to a reduction in heart rate at 16 months (Supplemental Figure 6A). 
End-diastolic LV wall thickness of  ROCKDNGata5-Cre mutants was significantly greater (Figure 10, D–F), 
with a corresponding decrease in end diastolic chamber diameter (Figure 10G), both from 10 months. 
Delta change in systolic-diastolic LV wall thickening was also significantly reduced (Figure 10H), and 
there was an overall significant increase in LV mass (Figure 10I), all from 10 months. No change in 
ejection fraction was observed (Supplemental Figure 6B). Analysis of  the MRI images between 4 and 8 
months showed that 67% of  ROCKDNGata5-Cre mutants had myocardial crypts in the LV wall, compared 
with 0% in the control mice (Supplemental Figure 6, C–F). These data demonstrate that the ROCKDN-
Gata5-Cre mutants developed LV concentric hypertrophy with systolic dysfunction as a consequence of  the 
preexisting cellular hypertrophy and sarcomeric disruption.
Discussion
We have shown that the early downregulation of  ROCK signaling in a proportion of  embryonic car-
diomyocytes at E9.25 caused the disruption of  sarcomeric structures in Cre-activated cardiomyocytes 
at E10.5. This led to reduced cardiomyocyte proliferation at E11.5 in ROCKDNGata5-Cre hearts. In these 
mutant embryos, by E15.5, the compact wall of  the ventricles was significantly thinner. Although, 
there was a significant increase in the thickness of  the compact wall at E16.5, the ventricular wall of  
postnatal mutant hearts remained thinner, with increased presence of  myocardial crypts. We propose 
that these intracellular abnormalities in sarcomeres, reduced cardiomyocyte proliferation, and delayed 
cardiomyocyte maturation led to the initiation of  compensatory cardiomyocyte hypertrophy through-
out the ventricular wall in late fetal stages of  development, causing the abnormal ventricular myo-
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Figure 8. Reduction in binding between ROCK and TnI proteins may account for reduced ph-TnI expression in ROCKDNGata5-Cre mutants, and increased 
phosphorylation by IBMX rescues the sarcomeric phenotype in vitro. (A–C) Immunofluorescence staining of ph-cTnI (green) in Cre-activated/GFP+ cells 
(red staining) in cardiomyocytes of control E10.5 hearts (yellow arrows). (D–F) There was a reduction in ph-cTnI staining in Cre-activated cardiomyocytes in 
ROCKDNGata5-Cre hearts (white arrows) compared with control samples (yellow arrows). n = 3 for each genotype. (G and H) Co-IP using protein extracts from 
whole heart lysates from E16.5 embryos showed that in control hearts, ROCK1 (158kDa) and ROCK2 (161 kDa), bind to cTnT (40 kDa) (G) and to cTnI (26 kDa) 
and ssTnI (22 kDa) (H). (I) In ROCKDNGata5-Cre mutant hearts, there was a significant reduction in binding between the ROCK proteins and the troponin pro-
teins. Co-IP with TnI showed a significant reduction in expression of ROCK1 and ROCK2, and conversely, in the same samples, co-IP with ROCK1 gave a sig-
nificant reduction in cTnI and ssTnI expression in ROCKDNGata5-Cre mutants. n = 4 for each genotype. (J–X) Primary cardiomyocytes were cultured from E15.5 
control and ROCKDNGata5-Cre mutants. GFP antibody was used to identify the Cre-activated (Cre+ve) cells (red staining), and cTnI antibody confirmed which 
cells were cardiomyocytes by labeling sarcomeres (green). Addition of IBMX to control cells did not have any effect (M–O). Cre-activated cardiomyocytes 
from ROCKDNGata5-Cre mutants, lacked sarcomeric structure (P–R). Addition of IBMX rescued the sarcomeric structure in Cre-activated cardiomyocytes from 
ROCKDNGata5-Cre mutants (S–U). Similar to the control samples, Cre– cells from ROCKDNGata5-Cre mutants had normal sarcomeric organization that was not 
altered following the addition of IBMX (V–X). (Y) The average number of sarcomeres per cardiomyocyte, from a total of 10 cells per well, was determined. 
There were no significant differences between control Cre+ cardiomyocytes with and without IBMX. There was a significant difference in sarcomere number 
between ROCKDNGata5-Cre Cre+ cardiomyocytes without IBMX compared with both control samples. Addition of IBMX to ROCKDNGata5-Cre Cre+ cardiomyocytes 
significantly increased sarcomeres, to a level that was no longer significantly different relative to both control groups; thus, addition of IBMX rescues 
the sarcomeric phenotype of ROCKDNGata5-Cre Cre+ cardiomyocytes. n = 3 for each genotype. Data are presented as mean ± SEM. *P < 0.05, **P < 0.01 by 
unpaired t test (I) and ****P < 0.0001 by 1-way ANOVA with Bonferroni’s correction for multiple comparisons (Y). Scale bars: 50 μm (A–F) and 10 μm (J–X).
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cardial wall development. The sarcomere disarray and cardiomyocyte hypertrophy persisted through 
postnatal and adult stages, causing re-expression of  fetal genes, cardiac fibrosis, and concentric LV 
hypertrophic growth at 9 months, which ultimately impaired cardiac function from 10 months (Figure 
11). Therefore, early disruption of  embryonic sarcomeres led to cellular abnormalities and alterations 
in cardiac function, hence reproducing many of  the clinical and histological features associated with 
the sarcomeric phenotype of  HCM in patients.
Thus, the data presented here from our detailed analysis of  ROCKDNGata5-Cre mice provides convincing 
evidence for a novel developmental origin for HCM. Few studies have focused on establishing whether 
Figure 9. Adult ROCKDNGata5-Cre mutants develop left ventricular hypertrophy, fibrosis, and re-expression of fetal genes from 9 months. (A and B) Four-
chamber-view sections of dissected hearts from P21 and 4-, 9-, and 12-month control and ROCKDNGata5-Cre mutants were stained with WGA to allow the 
average area of the cardiomyocytes to be calculated from left (A) and right (B) ventricles. In the left ventricle, cardiomyocytes were significantly larger in 
ROCKDNGata5-Cre mutants compared with controls at all ages, and in the right ventricle cardiomyocytes were significantly larger from 4 months (black lines). 
The average percent increase in cardiomyocyte size in ROCKDNGata5-Cre mutants compared with controls was calculated. In the ROCKDNGata5-Cre mutants, 
there was a significant change from 4 to 9 months (from 27% to 43%) and from 9 to 12 months (43% to 52%) in the left ventricle (C), with no correspond-
ing significant increase in the right ventricle (D). Hence, there was a specific increase in left ventricular hypertrophy in the ROCKDNGata5-Cre mutants. n=4 
P21, n = 3 4 months, n = 5 9 and 12 months, for each genotype. (E–H) qRT-PCR was used to detect any significant changes in gene expression using cDNA 
isolated from dissected hearts. In ROCKDNGata5-Cre mutants, compared with control hearts, there was a significant increase in the relative expression of fetal 
genes ANF and Myh7 from 9 months; and a significant decrease in expression of skeletal actin and phospholamban, which are dysregulated during hyper-
trophy. (I and J) Immunofluorescence staining with cTnI (green) showed disruption in sarcomere striations at 9 months throughout the heart in ROCKD-
NGata5-Cre mutants (J) compared with controls (I). (K and L) Patches of fibrosis were seen throughout the heart from 9 months, and there was a significant 
increase in the levels of fibrosis, calculated from fluorescence intensity measurements, in both ventricles at 9 and 12 months (M). n = 3 for each genotype 
at each time point for experiments in E–M. Data are presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 by 1-way ANOVA with 
Bonferroni’s correction for multiple comparisons. lv/LV, left ventricle; RV, right ventricle; M, month. Scale bars: 50 μm (I and J) and 100 μm (K and L).
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there are any embryonic defects in mouse models of  HCM, and therefore the intracellular abnormalities in 
sarcomeric structure that we report here could have been missed. Mutations in MYBPC3 account for a high 
proportion of  HCM cases (33), and in the Mybp3 KO mouse model, an embryonic phenotype was shown 
to predispose to HCM in adult mice (34). The study by Captur et al. focused on the emergence of  structural 
abnormalities (the presence of  myocardial crypts and abnormal trabecula patterns) in the ventricular wall 
during embryogenesis in their mutant mice, which were similar to our ROCKDNGata5-Cre mutant embryos. 
However, they, did not examine the ultrastructure of  embryonic sarcomeres or study the posttranslational 
modification of  troponin proteins in cardiomyocytes, which we propose is the underlying embryonic trigger 
for the progression toward HCM in adulthood.
Mutations in the sarcomeric genes associated with HCM, including cardiac actin and troponins, are 
thought to disrupt the normal biophysical properties of  the sarcomere, including sarcomere assembly (6). 
In ROCKDNGata5-Cre mutants expression of  ROCKDN led to the destabilization of  the sarcomeres at E10.5. 
ROCK is well known to play a major role in regulating the rearrangement of  actomyosin cytoskeleton (5) 
and myofibrillogenesis in cardiomyocytes, including the polymerization of  G-actin into actin filaments 
(F-actin) (35). We showed that this process was impeded by reduced ROCK activity, shown by the increase 
in G-actin accumulation and abnormal sarcomeric structure in vivo and in vitro.
Structurally, both TnT and TnI are known to be required for the correct assembly of  sarcomeres 
in early development (36–39), although it is not currently known whether phosphorylation of  the tro-
Figure 10. ROCKDNGata5-Cre mutants have features of hypertrophic cardiomyopathy, with increased left ventricular mass and reduced cardiac function from 
10 months. Heart function was assessed by cine cardiac MRI in mice aged 4–16 months. This identified a significant reduction in left (A) and right (B) ventricle 
stroke volume at 10 and 16 months in ROCKDNGata5-Cre compared with control hearts, with an overall significant reduction in cardiac output also from 10 months 
in ROCKDNGata5-Cre mutants compared with controls (C). (D–F) In MRI images, the left ventricular wall appears thicker in ROCKDNGata5-Cre mutants compared with 
controls (white lines in D and E). Measurements confirmed that there was a significant increase in end-diastolic left ventricular wall thickness in ROCKDNGa-
ta5-Cre hearts (F), with a corresponding significant decrease in end-diastolic chamber diameter (G), and a significant reduction in delta change in systolic-diastol-
ic left ventricular wall thickness (H) compared with controls, all from 10 months. There was an overall significant increase in LV mass/body weight ratio from 
10 months (I) compared with controls. n = 3 for 4 months, n = 3 for 6 months, n = 3 for 8 months, n = 5 for 10 months, n = 8 for 16 months, for each genotype. 
Data are presented as mean ± SEM. *P < 0.05, **P < 0.01, ****P < 0.0001 by 1-way ANOVA with Bonferroni’s correction for multiple comparisons. M, month.
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ponins specifically influences sarcomere assembly in embryonic cardiomyocytes. There are 2 isoforms 
of  TnI expressed in the heart, ssTnI and cTnI. ssTnI is the predominant embryonic and fetal isoform 
and is completely replaced by cTnI by 2–3 weeks postnatally (40). Interestingly, cTnI is first expressed at 
E10.5, which coincides which the emergence of  the sarcomeric disruption observed in the ROCKDNGa-
Figure 11. Loss of ROCK function in embryonic cardiomyocytes causes sarcomere disarray, leading to defects in 
ventricular wall development and compensatory fetal hypertrophy, predisposing to left ventricular hypertrophy, and 
ultimately HCM in adulthood. Disruption of ROCK signaling in embryonic cardiomyocytes in ROCKDNGata5-Cre mutants led 
to disruption of the sarcomeric structure and reduced phosphorylation of cTnI, ssTnI, and cTnT at E10.5. This reduced cell 
proliferation at E11.5 delayed cardiomyocyte maturation, resulting in compensatory fetal hypertrophy of the cardiomy-
ocytes throughout the heart by E16.5. The ventricular wall was significantly thinner and contained myocardial crypts 
between trabeculae, which along with hypertrophy and disruption of sarcomeric structure continued throughout the life 
of the ROCKDNGata5-Cre mice. There was a significant increase in left ventricular hypertrophy at 9 months, which led to an 
increase in expression of fetal genes, patches of fibrosis, increase in left ventricular mass, and reduced cardiac function 
from 10 months — all of which recapitulate features of the sarcomeric phenotype of HCM. Therefore, the developmental 
origin of HCM in ROCKDNGata5-Cre mice is sarcomeric disruption in embryonic cardiomyocytes, ultimately triggering patho-
logical left ventricular hypertrophy and maladaptive cardiac remodeling and cardiac dysfunction.
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ta5-Cre embryos at this age. ROCK phosphorylates cTnI (S23, S24, and T144 in mouse and T143 in human 
TNNI3) and cTnT (S278 and T287 in mouse and S285 and T294 in human TNNT2), which impacts the 
function of  myofilaments (4), and ROCK is predicted to phosphorylate ssTnI from in silico analysis 
(T51, S28, and S119) (41). Human HCM disease-causing mutations in residues R21 (R21C) and R145 
(R145G and R145Q) in TNNI3 were shown to specifically prevent the phosphorylation of  these key res-
idues (42). A mouse model of  the R21C mutation linked reduced phosphorylation of  cTnI to activation 
of  the fetal gene program, hypertrophy and fibrosis in adult mice (43), which is similar to our findings 
in ROCKDNGata5-Cre mice. The authors of  the aforementioned studies, however, did not look at sarcomeric 
structure in their cells or embryonic hearts. By co-IP we confirmed that ROCK proteins bind to cTnT, 
cTnI, and ssTnI and this interaction was reduced in the presence of  the ROCKDN protein, leading to 
reduced phosphorylation of  these proteins in embryonic hearts. Preliminary studies shown here, using 
the drug IBMX (known to elevate intracellular cAMP levels, leading to an increase in phosphorylation of  
TnI; ref. 32) on primary ROCKDNGata5-Cre cardiomyocytes, revealed a rescue of  the structural integrity of  
sarcomeres in Cre-activated cardiomyocytes compared with untreated ROCKDNGata5-Cre cardiomyocytes. 
Thus, this suggests for the first time to our knowledge that the phosphorylation of  troponins by ROCK 
may be involved in sarcomere assembly in embryonic cardiomyocytes. It is hoped that future in vitro 
studies will establish how loss of  phosphorylation by ROCK could directly lead to sarcomere disruption.
Similar to published mouse models of  HCM (44) and disease progression in humans (45), the appear-
ance of  cardiac dysfunction and progression toward heart failure in our ROCKDNGata5-Cre mice were delayed 
until adulthood. During development, there is normally a fetal phase of  physiological hypertrophy, which 
along with cell proliferation, accounts for the heart growth seen before birth (28). We showed that in 
ROCKDNGata5-Cre mutant embryos, there was a significant increase in hypertrophy in all cardiomyocytes, 
throughout the heart, from E16.5, which coincided with the increase in ventricular wall thickness at that 
age. We therefore hypothesize that in ROCKDNGata5-Cre mutants, there was an excessive increase in this fetal 
phase of  physiological hypertrophy compared with control embryos. This enabled the mutant hearts to com-
pensate for the earlier delay in ventricular wall development, hence allowing the ROCKDNGata5-Cre embryos 
to survive. Postnatally, the hypertrophic cardiomyocytes, throughout the whole heart from ROCKDNGata5-Cre 
mutants, remained at approximately the same significantly increased level of  physiological hypertrophy, 
with no impact on cardiac function up to 8 months. However, as the mouse matured further, this sustained 
persistent activation of  compensatory hypertrophic responses eventually triggered pathological hypertro-
phy, which is known to be associated with maladaptive cardiac remodeling and gradual cardiac dysfunction 
(46). In HCM, this remodeling is specifically linked with an increase in LV hypertrophy, the upregulation 
of  fetal gene expression, and the presence of  interstitial fibrosis (all of  which we saw at 9 months). This 
then leads to relaxation abnormalities in the heart (47) and an increase in LV mass and systolic dysfunction 
(which we saw at 10 months) in ROCKDNGata5-Cre mutants. Furthermore, an increase in myocardial crypts 
was found in presymptomatic ROCKDNGata5-Cre mice from E15.5 through to adulthood. This mirrors patients 
who are preclinical HCM mutation carriers, in whom cardiac structural abnormalities, including ventricu-
lar crypts (48) and abnormal trabecula patterning (49), have been identified.
Unexpectedly, we found that the expression level of the ROCKDN construct in the heart was significantly 
reduced to minimal levels from 3 months; hence ROCK function was only downregulated during embryogene-
sis and postnatally, and not in adulthood. This decrease in transcription is most likely due to the well-known epi-
genetic silencing of the CMV promoter by DNA methylation over time, as previously reported in mouse tissues 
(50–53). This is consistent with a previous report using the same ROCKDN transgenic mice, where there was no 
significant change in ROCK activity in 20-week-old hearts (19), suggesting that the expression of the ROCKDN 
construct had been silenced. Moreover, none of the previous publications using the ROCKDN mice have under-
taken a detailed analysis of ROCKDN expression, as presented here, and therefore this phenomenon may have 
been missed. Furthermore, the expression level of endogenous ROCK1 and ROCK2 genes was not altered in 
ROCKDNGata5-Cre mutants compared with controls. This was expected, as the ROCKDN protein forms homodi-
mers with endogenous ROCK1 and ROCK2 proteins (54) and therefore does not impede the expression of the 
ROCK genes. In adult animal models where hypertrophy has been induced, the application of ROCK inhibitors 
has been associated with decreasing hypertrophy (55), suggesting a role for ROCK in regulating hypertrophy 
and in the transition from cardiac hypertrophy to heart failure (13, 56). However, this scenario is different from 
our ROCKDNGata5-Cre model, as ROCK function was no longer downregulated in adult mice, and early embryonic 
disruption of ROCK was the developmental origin of the adult cardiomyopathy.
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In one study, ROCK was linked to the development of  a different form of  cardiomyopathy, arrhythmo-
genic RV cardiomyopathy (ARVC) (19). The authors utilized the same ROCKDN transgenic mice used in 
our study, but under the control of  either the αMHC-Cre (gave no phenotype) or the SM22a-Cre promoter, 
which gave rise to a model of  ARVC. The progression to disease differed from that in our ROCKDNGata5-Cre 
mice, as they had a severe postnatal phenotype and features associated with ARVC. In comparison to their 
results, we did not find any myocardial fibrofatty changes; no increase in expression of  Cnntb1, Wnt5b, or 
PPARγ; and no desmosomal abnormalities (Supplemental Figure 7). The discrepancy between the 2 models 
is most likely due to the influence of  different genetic backgrounds (57) and the different expression pat-
terns of  the Cre promoters. SM22α is expressed in the heart tube from E8.0, but expression decreases in the 
heart from E10.5, with no cardiac expression by E13.5, and becomes restricted to the smooth muscle cells 
of  the vasculature and visceral organs (58). In the Gata5-Cre and Tnt-Cre lines used in our study, Cre, and 
hence ROCKDN, is expressed in cardiomyocytes throughout development. Therefore, the sarcomere disar-
ray we observed at E10.5 persisted throughout development, spreading to the whole heart, which would 
more likely mimic the consequences of  a sarcomeric mutation in a patient who develops HCM.
As the clinical presentation of  HCM is very heterogeneous, it is even more important that the under-
lying complex pathophysiology of  this disease is understood. Our study highlights that there is a develop-
mental origin for HCM and the possibility that undetected nonlethal embryonic ventricular wall defects can 
predispose to cardiomyopathy later in life. Hence, it is important to unravel how early intracellular defects 
in the embryonic cardiomyocytes can go undetected and manifest as cardiovascular disease. Thus, the iden-
tification of  additional genetic variants in presymptomatic patients will provide individualized prognostic 
information and ensure early clinical investigations, which may show early signs of  structural or functional 
abnormalities, allowing targeted treatment to be developed. The ROCK genes are therefore potential candi-
date genes to add to the panel of  genes screened routinely in HCM patients.
Methods
Further information can be found in Supplemental Methods, available online with this article.
Mice. Transgenic ROCK dominant-negative (ROCKDN) mice (15) were intercrossed with the R26ReY-
FP reporter line (25). Cardiac-specific Cre lines were used to target ROCK downregulation in the myocar-
dium using TnT-Cre (22), the myocardium and epicardium using Gata5-Cre (23), and the epicardium using 
WT1-ERT-Cre (24). Genotyping primers are shown in Supplemental Table 1.
H&E, Sirius red, and oil red O staining. H&E and Sirius red staining were performed following standard 
protocols. Sirius red fluorescence was detected using the rhodamine channel (excitation 538–562 nm, emis-
sion 570–640 nm) (59), allowing quantification of  fibrosis within a tissue by measuring fluorescence inten-
sity using ImageJ (NIH) software. A total of  3 tissue-matched sections were analyzed per sample. Oil red 
O staining was performed to assess lipid content within heart sections following standard protocols. Slides 
were imaged using an Axio Imager 2 (Zeiss).
Immunofluorescence and immunohistochemistry. Staining was performed on paraffin-fixed embryonic and 
postnatal hearts, and cryosections from adult hearts. Sections were incubated with primary antibody over-
night at 4°C. Sections were washed and incubated with the appropriate secondary antibody. Slides were 
imaged using Axio Imager 2 and a Nikon A1R confocal. Antibodies are detailed in Supplemental Table 2.
Cardiomyocyte proliferation. Cardiomyocyte proliferation was analyzed in embryonic hearts by BrdU 
incorporation. Pregnant dams were given an i.p. injection of  25 mg/ml BrdU (MilliporeSigma) 1 hour 
prior to sacrifice. Embryos were fixed in paraformaldehyde at 4°C overnight, then processed through an 
ethanol series and embedded in paraffin. 8-μm tissue sections were collected, and IF was performed using 
BrdU antibody: Cre-activated cells were stained with GFP antibody and counterstained with DAPI. Cell 
counts were performed on 3 matched tissue sections for each sample. Between 2000 and 2500 cells were 
counted in both the LV and RV for each embryo, and the average was calculated.
qRT-PCR. Total RNA was isolated using the ReliaPrep RNA Miniprep System (Promega, catalog 
Z6010). cDNA was synthesized using a High-Capacity cDNA reverse transcription kit (Applied Biosys-
tems, catalog 4368814). qRT-PCR was performed using fast SYBR green mastermix (Life Technologies). 
Relative quantities of  gene expression were calculated and were normalized to the housekeeping gene Gap-
dh. qRT-PCR primers are listed in Supplemental Table 3.
Cardiomyocyte isolation. Primary cardiomyocytes were isolated from embryonic E15.5 or E17.5 hearts 
and treated with the ROCK inhibitor Y27632 or IBMX, as detailed in the Supplemental Methods.
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TEM. TEM was performed on E10.5 and E15.5 embryonic and 16-month adult heart tissue (Philips 
CM100; Electron Microscopy Research Services, Newcastle University) to assess sarcomere structure.
High-resolution episcopic microscopy. E15.5 embryos were collected and processed, and high-resolution 
episcopic microscopy (HREM) imaging was performed in-house (60).
Phosphoproteomics. Total protein was prepared from E13.5 embryonic hearts (individual younger 
hearts did not provide sufficient protein required for this assay), and primary cardiomyocytes, in 100 
μl CelLytic buffer (MilliporeSigma, C2978) with protease and phosphatase inhibitors. Western blot 
analysis was performed. Protein (20 μg) was separated via SDS-PAGE, transferred to a nitrocellulose 
membrane, and probed with primary antibodies (Supplemental Table 4). Membranes were incubated 
with the secondary antibody and visualized via ECL using the LI-COR C-DiGit. Phosphorylated 
protein was assessed using Pro-Q Diamond in-gel staining assay (Invitrogen, P33300) following the 
manufacturer’s instructions (61). Once stained, the gels were imaged, and the amount of  phosphory-
lated protein present was calculated. The gel was then stained with Coomassie blue (MilliporeSigma, 
B0770), allowing total protein to be calculated. The amount of  phosphorylated protein relative to total 
protein was calculated using ImageJ.
IP. Co-IP was performed with primary antibody immobilized onto magnetic Dynabeads Protein G or 
A (Invitrogen, 10007D) and incubated with total protein lysates from E16.5 control and ROCKDNGata5-Cre 
hearts overnight at 4°C. Supernatants were discarded, beads were washed and then protein was eluted and 
collected. Western blot analysis was then performed. Samples were then run on 4-12% Bis-Tris protein gels 
(Invitrogen, NP0322BOX) and probed using the appropriate antibody (Supplemental Table 4).
MRI. Cardiac cine MRI was performed as previously described (62). Scans were then converted to mat-
files using MATLAB script and LV and RV function analyzed using the freely available software Segment 
v1.8 (http://segment.heiberg.se).
ECG. Heart rate was measured in adult mice using a 3-lead ECG as described previously (63), and 
analysis was performed using LabChart software (ADInstruments).
Statistics. A normality test (Shapiro-Wilk) was performed on all the data. For nonparametric data, a 
Mann-Whitney U test was used, and for parametric data either an unpaired t test or 1-way ANOVA with 
Bonferroni’s correction for multiple comparisons was performed. A χ2 test was used to analyze Mendelian 
numbers. In all graphs, data are presented as mean ± SEM. Significance was deemed as P < 0.05. Analyses 
were performed using GraphPad Prism software (version 7.01).
Study approval. All mouse experiments were performed in accordance with the Animals (Scientific 
Procedures) Act 1986, United Kingdom, under project license PPL PC7996264. All experiments were 
approved by the Newcastle University Ethical Review Panel.
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